These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37847244)

  • 21. Rational Design of a New Class of Toll-Like Receptor 4 (TLR4) Tryptamine Related Agonists by Means of the Structure- and Ligand-Based Virtual Screening for Vaccine Adjuvant Discovery.
    Honegr J; Dolezal R; Malinak D; Benkova M; Soukup O; Almeida JSFD; Franca TCC; Kuca K; Prymula R
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29300367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of
    Franco AR; Sadones O; Romerio A; Artusa V; Shaik MM; Pasco ST; Italia A; D'Amato S; Anguita J; Huebner J; Romero-Saavedra F; Peri F
    J Med Chem; 2024 Apr; 67(7):5603-5616. PubMed ID: 38513080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants.
    Romerio A; Gotri N; Franco AR; Artusa V; Shaik MM; Pasco ST; Atxabal U; Matamoros-Recio A; Mínguez-Toral M; Zalamea JD; Franconetti A; Abrescia NGA; Jimenez-Barbero J; Anguita J; Martín-Santamaría S; Peri F
    J Med Chem; 2023 Feb; 66(4):3010-3029. PubMed ID: 36728697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving the immunostimulatory potency of diethanolamine-containing lipid A mimics.
    Lewicky JD; Ulanova M; Jiang ZH
    Bioorg Med Chem; 2013 Apr; 21(8):2199-2209. PubMed ID: 23490149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
    Strobl S; Hofbauer K; Heine H; Zamyatina A
    Chemistry; 2022 Jun; 28(35):e202200547. PubMed ID: 35439332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of TLR4 agonist activity: formulation effects.
    Misquith A; Fung HW; Dowling QM; Guderian JA; Vedvick TS; Fox CB
    Colloids Surf B Biointerfaces; 2014 Jan; 113():312-9. PubMed ID: 24121074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.
    Baldwin SL; Hsu FC; Van Hoeven N; Gage E; Granger B; Guderian JA; Larsen SE; Lorenzo EC; Haynes L; Reed SG; Coler RN
    Front Immunol; 2018; 9():295. PubMed ID: 29515589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.
    Airhart CL; Rohde HN; Hovde CJ; Bohach GA; Deobald CF; Lee SS; Minnich SA
    Vaccine; 2008 Oct; 26(44):5554-61. PubMed ID: 18722493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.
    Heine H; Adanitsch F; Peternelj TT; Haegman M; Kasper C; Ittig S; Beyaert R; Jerala R; Zamyatina A
    Front Immunol; 2021; 12():631797. PubMed ID: 33815382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.
    Ireton GC; Reed SG
    Expert Rev Vaccines; 2013 Jul; 12(7):793-807. PubMed ID: 23885824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV.
    Poteet E; Lewis P; Chen C; Ho SO; Do T; Chiang S; Labranche C; Montefiori D; Fujii G; Yao Q
    Vaccine; 2016 Nov; 34(48):5886-5894. PubMed ID: 27997339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
    Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
    Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymeric Pathogen-Like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus.
    Kingstad-Bakke B; Toy R; Lee W; Pradhan P; Vogel G; Marinaik CB; Larsen A; Gates D; Luu T; Pandey B; Kawaoka Y; Roy K; Suresh M
    Front Immunol; 2020; 11():559382. PubMed ID: 33767689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.
    Gandhapudi SK; Chilton PM; Mitchell TC
    PLoS One; 2013; 8(2):e56855. PubMed ID: 23457630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Haupt RE; Harberts EM; Kitz RJ; Strohmeier S; Krammer F; Ernst RK; Frieman MB
    Vaccine; 2021 Aug; 39(36):5205-5213. PubMed ID: 34362603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced efficacy of a multi-epitope vaccine for type A and O foot‑and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist.
    Lei Y; Shao J; Ma F; Lei C; Chang H; Zhang Y
    Mol Immunol; 2020 May; 121():118-126. PubMed ID: 32199211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.
    Lambert SL; Yang CF; Liu Z; Sweetwood R; Zhao J; Cheng L; Jin H; Woo J
    PLoS One; 2012; 7(12):e51618. PubMed ID: 23284726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.
    Fox CB; Moutaftsi M; Vergara J; Desbien AL; Nana GI; Vedvick TS; Coler RN; Reed SG
    Vaccine; 2013 Dec; 31(49):5848-55. PubMed ID: 24120675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.